Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Antibe Therapeutics Inc (ATE.TO)

Antibe Therapeutics Inc (ATE.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Antibe Therapeutics Inc 15 Prince Arthur Avenue Toronto ON M5R 1B2 CAN

P: 905-570-5103

Description:

Antibe Therapeutics Inc develops and out-licenses new pharmaceuticals. Its main objective is to develop its lead compound otenaproxesul, by satisfying the requirements of the relevant drug regulatory authorities while also satisfying the commercial licensing objectives of prospective global partners. It operates in two segments: Antibe and Citagenix. All of its revenue is generated from the Citagenix segment, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. Citagenix consists of branded biologics and medical devices that promote bone regeneration. The company's geographical segments are Canada, the United States, Europe, and the Rest of the World.

Key Statistics

Overview:

Market Capitalization, $K 35,623
Shares Outstanding, K 51,627
Annual Sales, $ 9,713 K
Annual Net Income, $ -26,301 K
Last Quarter Sales, $ 2,727 K
Last Quarter Net Income, $ -6,299 K
60-Month Beta 0.15
% of Institutional Shareholders 0.59%

Growth:

1-Year Return -83.13%
3-Year Return -77.00%
5-Year Return -62.70%
5-Year Revenue Growth 17.00%

Per-Share Information:

Next Earnings Date 02/11/22
Earnings Per Share ttm -0.67
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year -21.25%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 12/01/20

ATE.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -54.03%
Return-on-Assets % -39.09%
Profit Margin % -270.78
Net Margin % -2.44
Debt/Equity 0.00
Price/Sales 2.53
Price/Book 0.50
Book Value/Share 1.39
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar